The presence of RAS mutations may contribute supportive evidence favoring a diagnosis of NIFTP, follicular adenoma, or follicular carcinoma, in contrast to BRAF mutations which are more commonly observed in association with classical papillary thyroid carcinoma [12–14]. The gene discussed is BRAF; the disease is thyroid gland follicular carcinoma.